(STIM) Neuronetics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(STIM) Neuronetics, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Neuronetics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
NeuroStar Advanced Therapy System
NeuroStar Advanced Therapy System is Neuronetics, Inc. flagship FDA-cleared TMS platform and still drives most of its revenue, which was about $68.8 million in 2024. The U.S. non-drug depression-treatment market keeps growing as major depression affects about 21 million adults a year, and TMS use is rising as access expands. In BCG terms, it fits a Star: high share in a growing market.
Adolescent depression label
Adolescent depression is a newer NeuroStar use case, so it is still early in the adoption curve but can widen Neuronetics, Inc.'s addressable market beyond adult MDD. In the U.S., about 5 million adolescents had a major depressive episode in the latest NIMH readout, which supports a larger long-run pool. That makes this a higher-growth Stars franchise driver.
Direct psychiatrist sales channel
Neuronetics, Inc.’s direct psychiatrist sales channel is a Star because it links field reps straight to prescribing doctors, which drives system placements and patient starts.
That model matters in a market where specialty mental-health care keeps growing, and it gives Neuronetics tighter control over adoption and follow-up.
Because sales are tied to psychiatrist demand, the channel can scale as more clinics add non-drug depression treatment.
Greenbrook clinic platform
Greenbrook clinic platform gives Neuronetics direct treatment access through owned sites, so it can capture more patient volume and local referrals. The platform expansion supports the company’s growth push in a market where TMS demand rose after Neuronetics reported 2025 revenue of $90.2 million and a narrowed net loss of $24.1 million.
- Direct patient access
- More local referrals
- Supports clinic growth
TMS adoption trend
Office-based TMS is gaining traction as more clinicians and patients choose non-surgical, non-drug care. Roughly 30% of major depressive disorder patients do not respond to first-line antidepressants, which keeps demand for alternatives high. For Neuronetics, Inc., that widening acceptance supports the Stars profile and a market-growth backdrop.
- More provider adoption
- More patient demand
- High unmet need persists
NeuroStar Powers Neuronetics’ Fast-Growing Revenue Engine
NeuroStar is Neuronetics, Inc.'s main Star: it generated most 2024 revenue at about $68.8 million and sits in a growing TMS market as major depression affects about 21 million U.S. adults a year. The 2025 revenue rise to $90.2 million plus Greenbrook and direct psychiatrist sales support its high-growth, high-share profile.
| Star driver | Data |
|---|---|
| 2025 revenue | $90.2 million |
| 2024 revenue | $68.8 million |
| U.S. MDD adults | 21 million |
What is included in the product
Detailed Word Document
Neuronetics BCG Matrix: maps its products by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
One-page Neuronetics BCG Matrix that quickly spots pain points and growth bets by quadrant
Reference Sources
Provides a credible source trail for Neuronetics, Inc., helping teams verify assumptions fast and make better decisions.
Cash Cows
Adult MDD installed base
Adult MDD is Neuronetics, Inc.'s oldest and most proven revenue base, and it stays sticky because major depressive disorder affects about 21.0 million U.S. adults each year. Growth is slower than newer uses, but the installed base supports repeat treatment demand and steadier cash generation. That makes it the clearest Cash Cow in the BCG Matrix.
Service and maintenance revenue
Service and maintenance revenue is a cash cow for Neuronetics, Inc. because every installed NeuroStar system needs training, service, and upkeep after sale. This recurring income is steadier than new device placements and comes from an existing customer base, so it helps smooth cash flow. In BCG terms, it turns the installed base into repeat revenue with lower demand risk.
Replacement system sales
Replacement system sales let Neuronetics, Inc. sell newer systems to existing customers, so the company can earn repeat revenue from its installed base. This is less risky than landing a first placement because the buyer already knows the workflow and clinical value.
That makes the segment a cash cow: it helps protect cash flow, supports service and consumable pull-through, and can lift revenue without the same sales cost as a new site win.
Reimbursed repeat treatments
Approved outpatient Neuronetics treatments, especially the standard acute TMS course of up to 36 sessions, can be billed again across patients and repeat visits. That reimbursement makes utilization steadier and helps the mature base stay cash generative.
- Up to 36 billable sessions per course
- Repeat use supports stable volume
- Reimbursement lowers demand swings
Existing psychiatrist accounts
Neuronetics already has a nationwide psychiatry sales footprint, so existing psychiatrist accounts are a cash cow: the rep network is in place, training costs are lower, and renewal-style selling is cheaper than landing new clinics. As the addressable market matures, these installed accounts should support better gross margin and operating leverage.
- Nationwide sales coverage is already built.
- Installed accounts cut future selling friction.
- Lower CAC helps protect margins.
Neuronetics’ Cash Cows: Adult MDD, Recurring Service, and Replacements
Neuronetics, Inc.'s Cash Cows are the mature NeuroStar adult MDD base, recurring service revenue, and replacement sales. Adult MDD supports steady demand, while installed systems drive repeat maintenance and training income. Up to 36 reimbursable sessions per course help keep volume stable.
| Cash Cow | Signal |
|---|---|
| Adult MDD | 21.0M U.S. adults |
| Service | Recurring revenue |
| Replacement | Lower CAC |
Get Your Copy
Neuronetics, Inc. Reference Sources
You're previewing the exact Neuronetics, Inc. BCG Matrix document you'll receive after purchase. The final file includes the same analysis, formatting, and structure shown here. No demo version or hidden content—just the complete, ready-to-use report. Once purchased, it’s instantly available for download.
Dogs
Small ex-U.S. sales
Neuronetics, Inc.'s ex-U.S. sales stayed a small slice of the 2025 mix, with the company still heavily tied to the U.S. market. That makes this a Dogs-style channel: low share, slower adoption, and limited scale outside the home market.
In 2025, the core business generated about $80 million in revenue, while international activity remained immaterial by comparison. With no clear step-up in overseas uptake, these channels still lag the U.S. base.
Underutilized clinic sites
Neuronetics, Inc. has clinic sites that can still carry rent, staff, and equipment costs even when patient flow is thin, so margins get squeezed fast. If a location is not filling visits, that fixed-cost drag makes it a Dog in BCG terms. The latest reported filings still show a loss-making profile, which fits the low-utilization risk.
Legacy low-volume SKUs
Legacy low-volume SKUs are the least strategic part of Neuronetics, Inc.'s mix, since older configurations add complexity but little growth. They still need parts, service, and inventory control, which ties up cash and ops time. Upside is limited, so pruning them can protect margin and free attention for the main platform.
Weak coverage channels
Weak coverage channels stay a Dogs area for Neuronetics, Inc. because reimbursement uncertainty keeps patient volume low, so the channel cannot build steady scale. When payment support is thin, margin pressure rises and each new site adds less profit. That makes growth slow and the channel hard to expand.
- Unclear reimbursement limits referrals.
- Low payment support weakens margins.
- Scale stays hard without volume.
Non-core support assets
Non-core support assets sit in the Dog bucket because they add little to Neuronetics, Inc.'s core depression-treatment growth engine and can drain scarce management time. If they do not improve revenue or margin, they are better sized down or sold. The clean test is simple: if an asset is not helping scale the TMS franchise, it is a pruning candidate.
- Low strategic fit
- Weak growth profile
- Management time drag
- Prune or exit
Neuronetics’ Dogs: Low-Scale Assets Dragging Growth and Margins
Dogs in Neuronetics, Inc. are the low-share, low-scale pieces of the business: ex-U.S. sales stayed immaterial in 2025, while total revenue was about $80 million. Weak reimbursement, thin clinic volume, and fixed site costs keep these units from scaling.
Older low-volume SKUs and non-core support assets also fit the Dog bucket because they add cost more than growth. The latest filings still point to a loss-making profile, so pruning looks better than expansion.
| Dog area | 2025 signal | BCG read |
|---|---|---|
| Ex-U.S. sales | Immaterial vs. ~$80M total revenue | Low share |
| Clinic sites | Fixed costs, thin volume | Margin drag |
| Legacy SKUs | Little growth, added complexity | Prune |
Question Marks
Additional psychiatric indications
Additional psychiatric indications are a real question mark for Neuronetics, Inc.: any label expansion could open a much larger pool than its current FDA-cleared uses, but only if trials show clear benefit and regulators agree. In the meantime, these programs sit in the high-upside bucket because success could add new revenue streams, while failure leaves them with little value. The bet is still on proof, and proof is the expensive part.
Geographic expansion
Neuronetics’ geographic expansion is a Question Mark because wider U.S. and international rollout could lift access, but share is still unclear. In 2025, the company is still scaling its NeuroStar installed base and reimbursement reach, so each new market can add demand, yet adoption depends on clinic onboarding and payer coverage. The upside is real, but execution risk stays high.
Digital referral tools
Neuronetics, Inc.’s digital referral tools fit a question mark: they can lift treatment starts by making it easier to move patients into therapy, but they are not yet a core cash engine. With major depressive disorder affecting about 21 million U.S. adults each year, even small gains in referral speed can matter. Their value still depends on adoption by clinicians and patients.
New clinic openings
New clinic openings can lift Neuronetics, Inc. volume fast, but each site needs cash, staff, and payer approval, so returns can swing hard. That is why this sits in the Question Marks quadrant: high growth upside, but also high execution risk. If new sites fill fast and secure reimbursement, they can become strong revenue drivers; if not, they drain margin.
- Fast volume growth
- High setup cost
- Needs payer support
- Execution risk stays high
Coverage expansion efforts
Coverage expansion is the key Question Mark for Neuronetics, Inc.: broader payer access can lift patient starts and utilization, but until coverage deepens, payback stays hard to predict. In 2025, the company still faced an uneven reimbursement base, so each new payer win matters more than small demand swings.
- More coverage = more eligible patients
- Adoption upside can be large
- Returns stay uncertain until coverage broadens
Neuronetics’ Question Marks: High Upside, High Risk
Neuronetics, Inc.’s Question Marks are still high-upside bets: they could grow fast if trials, payer coverage, and clinic adoption improve, but they burn cash until proof arrives. In 2025, that matters because each win can open access to millions of patients, including about 21 million U.S. adults with major depressive disorder. The risk is simple: no proof, no scale.
| Item | Signal |
|---|---|
| Question Marks | High upside, high risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.